AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer. The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit...

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...

AbbVie’s expanded partnership with Harpoon is the company’s second deal in as many days focused on developing trispecific engager therapies. While the Harpoon deal is focused on T cell therapies, the other, with Dragonfly, could...

Harpoon Therapeutics Inc. (NASDAQ:HARP) raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon sold 5.4 million shares at $14, within the $13-$15 range. The price gave Harpoon a...

Harpoon Therapeutics Inc. (NASDAQ:HARP) shares lost $0.50 to $13.50 in their first day of trading Friday after the company raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon...

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed on Dec. 27 to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing...

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed Thursday to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing tri-specific T...

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million on Nov. 11 in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of...

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of its T cell...

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...